Go Pro
Daniil Gataulin

Daniil Gataulin Analyst Performance

Senior Research Analyst, Ophthalmology at Chardan Capital

Daniil Gataulin is a stock analyst at Chardan Capital in the healthcare sector, covering 19 publicly traded companies. Over the past year, Daniil Gataulin has issued 46 stock ratings, including strong buy, buy, and hold recommendations. While full access to Daniil Gataulin's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Daniil Gataulin's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
90 Last 1 Years
Buy Recommendations
91.11% 82 Buy Ratings
Companies Covered
19 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy1.1%1 ratings
Buy90.0%81 ratings
Hold8.9%8 ratings
Sell0.0%0 ratings

Out of 90 total stock ratings issued by Daniil Gataulin at Chardan Capital, the majority (90.0%) have been Buy recommendations, followed by 8.9% Hold and 1.1% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
19 companies

Daniil Gataulin, an analyst at Chardan Capital, currently covers 19 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
19 companies
100.0%

Daniil Gataulin of Chardan Capital specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
13 companies
68.4%
PHARMACEUTICALS
6 companies
31.6%

About Daniil Gataulin

Dr. Daniil Gataulin is a Senior Research Analyst at Chardan covering Biotech companies with a focus on ophthalmology. Dr. Daniil Gataulin joined Chardan in the summer of 2021 as a VP, Senior Research Associate covering Biotechnology. Prior to Chardan, he held a Senior Research Associate position at Raymond James, where he covered SMID biotech companies with the focus on neurology, hematology, and gene therapy. Prior to his role at Raymond James, Dr. Gataulin studied the mechanism of DNA repair and recombination in the laboratory of Dr. Doug Bishop at the University of Chicago, where he discovered a novel role for ATP hydrolysis by a DNA repair/recombination protein. Dr. Gataulin holds a BS in Cell Molecular Biology from Grand Valley State University, Master’s degree in Biotechnology from Illinois Institute of Technology, and a PhD in Molecular Genetics and Cell Biology from the University of Chicago.
Follow on LinkedIn

Daniil Gataulin's Ratings History at Chardan Capital

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
CervoMed Inc. stock logo
CRVO
CervoMed
8/3/2026Upgrade$2.81Strong-Buy
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
5/11/2026Upgrade$41.01$61.00Buy
uniQure N.V. stock logo
QURE
uniQure
4/30/2026Boost Price Target$19.95$37.00Buy
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
3/27/2026Reiterated Rating$1.08$4.00Buy
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
3/27/2026Reiterated Rating$7.53$35.00Buy
Ocugen, Inc. stock logo
OCGN
Ocugen
3/25/2026Reiterated Rating$1.96$7.00Buy
Zura Bio Limited stock logo
ZURA
Zura Bio
3/23/2026Boost Price Target$5.50$11.00Buy
Annexon, Inc. stock logo
ANNX
Annexon
3/20/2026Reiterated Rating$5.49$16.00Buy
CervoMed Inc. stock logo
CRVO
CervoMed
3/18/2026Boost Price Target$4.53$21.00Buy
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
3/12/2026Boost Price Target$5.01$11.00Buy
uniQure N.V. stock logo
QURE
uniQure
3/9/2026Boost Price Target$17.29$31.00Buy
CervoMed Inc. stock logo
CRVO
CervoMed
3/5/2026Reiterated Rating$4.02$15.00Buy
Ocugen, Inc. stock logo
OCGN
Ocugen
3/5/2026Reiterated Rating$1.96$7.00Buy
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
3/4/2026Boost Price Target$18.00$29.00Buy
uniQure N.V. stock logo
QURE
uniQure
3/3/2026Lower Price Target$10.50$16.00Buy
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2/18/2026Reiterated Rating$0.42Neutral
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
2/18/2026Reiterated Rating$6.99$21.00Buy
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
2/10/2026Lower Price Target$10.31$50.00Buy
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
1/29/2026Reiterated Rating$11.01$52.00Buy
Ocugen, Inc. stock logo
OCGN
Ocugen
1/20/2026Reiterated Rating$1.69$7.00Buy
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
12/23/2025Initiated Coverage$10.06$19.00Buy
Annexon, Inc. stock logo
ANNX
Annexon
12/23/2025Initiated Coverage$5.19$16.00Buy
Annexon, Inc. stock logo
ANNX
Annexon
12/23/2025Initiated Coverage$5.11$16.00Buy
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
12/23/2025Initiated Coverage$9.66$19.00Buy
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
12/9/2025Reiterated Rating$16.11$21.00Buy
uniQure N.V. stock logo
QURE
uniQure
12/4/2025Reiterated Rating$22.21$53.00Buy
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
11/20/2025Reiterated Rating$10.93$52.00Buy
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
11/17/2025Reiterated Rating$14.08$61.00Buy
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
11/17/2025Reiterated Rating$19.51$14.00Neutral
Zura Bio Limited stock logo
ZURA
Zura Bio
11/14/2025Reiterated Rating$4.08$10.00Buy
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
11/13/2025Reiterated Rating$1.92$9.00Buy
Oculis Holding AG stock logo
OCS
Oculis
11/11/2025Reiterated Rating$19.42$51.00Buy
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
11/11/2025Reiterated Rating$8.55$35.00Buy
uniQure N.V. stock logo
QURE
uniQure
11/11/2025Reiterated Rating$26.15$53.00Buy
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
11/7/2025Reiterated Rating$1.92$9.00Buy
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
11/5/2025Reiterated Rating$10.90$21.00Buy
uniQure N.V. stock logo
QURE
uniQure
11/3/2025Lower Price Target$34.29$53.00Buy
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
10/27/2025Downgrade$4.24Hold
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
10/16/2025Initiated Coverage$2.00$9.00Buy
Oculis Holding AG stock logo
OCS
Oculis
10/8/2025Boost Price Target$19.06$51.00Buy
Gold just passed our debt as the world's #1 asset (Ad)

China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low. Beijing's central bank has bought gold for 20 straight months, its longest streak in a decade. Goldman Sachs estimates China's real gold buying is 4.8 times the official figure. The European Central Bank confirms gold has overtaken US Treasuries as the world's top reserve asset, at 27% versus 22%. As foreign demand for US debt fades, rates and everyday costs may feel the pressure.tc pixel

See what's driving the global shift toward gold now
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
10/6/2025Reiterated Rating$15.45$14.00Neutral
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
10/2/2025Reiterated Rating$11.04$21.00Buy
Zura Bio Limited stock logo
ZURA
Zura Bio
9/30/2025Reiterated Rating$2.99$10.00Buy
uniQure N.V. stock logo
QURE
uniQure
9/25/2025Boost Price Target$47.50$76.00Buy
Ocugen, Inc. stock logo
OCGN
Ocugen
9/19/2025Reiterated Rating$1.40$7.00Buy
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
9/15/2025Initiated Coverage$12.81$21.00Buy
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
9/10/2025Downgrade$47.64$48.00Neutral
uniQure N.V. stock logo
QURE
uniQure
9/8/2025Reiterated Rating$17.95$35.00Buy
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
9/8/2025Reiterated Rating$9.71$52.00Buy
uniQure N.V. stock logo
QURE
uniQure
8/29/2025Reiterated Rating$16.26$35.00Buy
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
8/28/2025Reiterated Rating$1.09$3.00Neutral
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
8/15/2025Reiterated Rating$10.82$61.00Buy
Zura Bio Limited stock logo
ZURA
Zura Bio
8/15/2025Reiterated Rating$1.72$10.00Buy
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
8/15/2025Reiterated Rating$2.43$3.00Neutral
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
8/15/2025Reiterated Rating$8.33$35.00Buy
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
8/14/2025Reiterated Rating$21.77$70.00Buy
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
8/13/2025Reiterated Rating$2.58$33.00Buy
CervoMed Inc. stock logo
CRVO
CervoMed
8/11/2025Reiterated Rating$9.85$15.00Buy
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
8/8/2025Reiterated Rating$7.90$52.00Buy
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
8/8/2025Reiterated Rating$0.68$4.00Buy
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
8/7/2025Reiterated Rating$10.58$27.00Buy
Ocugen, Inc. stock logo
OCGN
Ocugen
8/4/2025Reiterated Rating$0.99$7.00Buy
uniQure N.V. stock logo
QURE
uniQure
7/29/2025Lower Price Target$13.68$35.00Buy
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
7/18/2025Downgrade$0.60Neutral
Ocugen, Inc. stock logo
OCGN
Ocugen
6/24/2025Reiterated Rating$0.98$7.00Buy
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
6/24/2025Reiterated Rating$12.76$61.00Buy
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
6/9/2025Reiterated Rating$9.61$52.00Buy
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
5/15/2025Reiterated Rating$1.88$33.00Buy
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
5/14/2025Lower Price Target$5.15$35.00Buy
Ocugen, Inc. stock logo
OCGN
Ocugen
5/12/2025Reiterated Rating$0.67$7.00Buy
Oculis Holding AG stock logo
OCS
Oculis
5/9/2025Boost Price Target$18.70$33.00Buy
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
5/8/2025Lower Price Target$0.35$4.00Buy
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
5/8/2025Lower Price Target$6.09$27.00Buy
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
4/23/2025Initiated Coverage$17.32$70.00Buy
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
4/17/2025Lower Price Target$2.98$33.00Buy
Oculis Holding AG stock logo
OCS
Oculis
4/17/2025Reiterated Rating$18.02$28.00Buy
uniQure N.V. stock logo
QURE
uniQure
4/1/2025Initiated Coverage$10.60$38.00Buy
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
4/1/2025Lower Price Target$7.43$61.00Buy
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
3/28/2025Reiterated Rating$15.45$90.00Buy
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
3/21/2025Lower Price Target$0.43$8.00Buy
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
3/20/2025Reiterated Rating$8.50$52.00Buy
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
3/14/2025Reiterated Rating$6.55$52.00Buy
Oculis Holding AG stock logo
OCS
Oculis
3/13/2025Reiterated Rating$18.84$28.00Buy
Ocugen, Inc. stock logo
OCGN
Ocugen
3/6/2025Boost Price Target$0.57$7.00Buy
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
3/6/2025Reiterated Rating$6.82$33.00Buy
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
2/26/2025Reiterated Rating$0.50$11.00Buy
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
2/24/2025Reiterated Rating$7.30$36.00Buy
Ocugen, Inc. stock logo
OCGN
Ocugen
2/13/2025Reiterated Rating$0.66$6.00Buy
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
2/6/2025Reiterated Rating$7.80$33.00Buy
Ocugen, Inc. stock logo
OCGN
Ocugen
1/23/2025Reiterated Rating$0.75$6.00Buy
Print this before your next trade (Ad)

Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon.tc pixel

Download your free copy of the Smart Trade Options Checklist now